Willingness to prescribe | ||||
---|---|---|---|---|
Overall, % | Unwilling, % | Willing, % | P-value | |
Evidence for the benefits of the drug | 95.0 | 87.6 | 97.2 | <0.001 |
The existence of NICE guideline (or national equivalent) | 95.0 | 87.6 | 97.2 | <0.001 |
Patient awareness of possible harms and benefits | 94.1 | 81.9 | 97.6 | <0.001 |
The patient’s level of risk for breast cancer | 93.8 | 82.9 | 96.9 | <0.001 |
Patient interest in taking tamoxifen | 90.6 | 74.8 | 95.3 | <0.001 |
GPs’ confidence in their knowledge of tamoxifen | 89.5 | 83.3 | 91.4 | 0.001 |
Evidence for the harms of the drug | 89.3 | 89.0 | 89.4 | 0.880 |
The patient’s support from the family history cliniciana | 88.6 | 69.0 | 94.3 | <0.001 |
First prescription being made by family history clinician | 86.0 | 72.7 | 88.4 | <0.001 |
Policy of GPs’ clinical commissioning group | 80.2 | 82.4 | 79.5 | 0.360 |
Prescribing off-label | 74.6 | 91.4 | 69.6 | <0.001 |
The first prescription being made by GP | 71.9 | 85.0 | 66.0 | <0.001 |
Attitudes of colleagues at the same career stage | 61.6 | 57.6 | 32.8 | 0.170 |
Attitudes of more senior colleagues | 59.4 | 58.1 | 59.7 | 0.670 |
Prescribing budget in GPs’ general practice | 42.1 | 41.4 | 42.3 | 0.810 |
Financial costs of tamoxifen | 41.4 | 37.6 | 42.5 | 0.210 |
↵a This item was only asked of those GPs allocated to the relevant condition. NICE = National Institute for Health and Care Excellence.